Efficacy and Safety of Baloxavir Marboxil in Influenza Patients aged 75 or Over： A Sub-Group Analysis of CAPSTONE-2 Study

Background ： Elderly subjects aged 75 or over with influenza are considered at high risk of developing severe influenza and influenza-related complications. Therefore, early therapeutic intervention with anti-influenza medications is more important in elderly patients. randomized of global phase III study in patients at high risk of influenza-related complications (CAPSTONE-2, N=2,184) analyzed in a subgroup of patients 75 years of or older (N=156). The primary endpoint the to improvement of (TTIIS). The clinical secondary endpoints the resolution of and the virological secondary endpoints included the change in infectious virus titer. In addition, adverse events were also assessed as the safety endpoint. compared to the placebo or oseltamivir group. In regard to adverse events, no clear differences were observed among three groups. Conclusions ： Baloxavir was superior to placebo in alleviating the symptoms of influenza in patients aged 75 or older. The results suggest a larger treatment benefit of baloxavir as compared to that of oseltamivir, based on the greater degree of reduction in the influenza virus titers.